Biotech Values

[DewDiligence]

OVAS reverse-merges into Millendo Therapeutics:

https://finance.yahoo.com/news/ovascience-millendo-therapeutics-announce-merger-110000900.html

The merged company will focus on advancing Millendo’s pipeline of distinct and transformative treatments for orphan endocrine diseases.

Upon shareholder approval, the combined company is expected to operate under the name Millendo Therapeutics and trade on the Nasdaq Capital Market under the ticker symbol MLND.

…current OvaScience shareholders will own approximately 20% of the combined company and current Millendo investors will own approximately 80% of the combined company (before accounting for the additional financing transaction).